SCHEMBL5136596

SCHEMBL5136596

CCCCn1c(CN(CC=Cc2cc(OC)ccc2OC)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.47
HTR2A P28223 8/20 0.41
HTR2C P28335 8/20 0.41
HTR2B P41595 8/20 0.41
TP53 P04637 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
MAPT P10636 2/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
ADRB1 P08588 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
DRD1 P21728 1/20 0.36
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136593 1.00 C5AR1 (0.47) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5137323 0.91 C5AR1 (0.51) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5137687 0.89 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5137690 0.89 C5AR1 (0.49) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5137286 0.87 C5AR1 (0.52) C5AR1SMN1; SMN2PPARGPPARATDP1
SCHEMBL5137287 0.87 C5AR1 (0.52) C5AR1SMN1; SMN2PPARGPPARATDP1
SCHEMBL5135424 0.87 C5AR1 (0.46) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5135423 0.87 C5AR1 (0.46) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5136237 0.86 C5AR1 (0.55) C5AR1HTR2AHTR2CHTR2BTP53
SCHEMBL5137546 0.86 HTR2A (0.49) C5AR1HTR2AHTR2CHTR2BTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed